Initial Stereax M300 Shipments
RNS Number : 0272M
Ilika plc
18 December 2025
18 December 2025
Ilika plc
('Ilika,' the 'Company,' or the 'Group')
Ilika Announces Initial Stereax M300 Shipments
Commencement of Shipping Marks Important Commercial Milestone
Ilika (AIM: IKA), the UK pioneer in solid state battery technology, announces it has commenced shipping prototype Stereax M300s to customers, meeting an important commercial milestone.
These initial deliveries will be allocated to the 21 customers which form Ilika's existing order book, many of whom have previously received Stereax batteries for evaluation from the Company's UK pilot line. A number of batteries from the initial batches will be allocated to the extensive M300 testing programme, which is designed to generate a larger body of test data relevant to exciting applications in active implantable medical devices (AIMDs). Applications include powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices. With its small footprint and enhanced charging capabilities, Stereax is ideally suited to meet the needs of AIMDs, offering benefits that include: reduced surgery time, the ability to place the implant closer to the point of therapy, long-lasting performance, user recharging at home and the ability to power Bluetooth radio. Ilika and its strategic partner, Cirtec Medical Corp, will solicit feedback from this core customer group to verify customer experience before ramping production.
This milestone progresses the 10-year manufacturing agreement signed in August 2023, in which Cirtec Medical, a leading US medical device manufacturer, will produce Ilika's Stereax battery portfolio.
Daniel Weinstein, Co-Founder and Chief Executive Officer at Lura Health, a provider of non-invasive health management solutions using continuous salivary monitoring, said: "As one of the first customers to receive M300 prototypes, we are excited to be working with Ilika and Cirtec Medical to demonstrate the deployment of Stereax miniature batteries in our range of non-invasive microsensors for salivary health markers."
Shawn Martin, Vice President at Cirtec Medical, said: "The Stereax product is an excellent addition to our world-leading capabilities in advanced miniaturised electronics designed for life-changing medical devices."
Graeme Purdy, CEO of Ilika, said: "After successfully transferring Stereax technology to Cirtec Medical's world-class manufacturing facility in Lowell, Massachusetts, we are looking forward to intensifying our customer engagement and servicing their needs for implantable power management devices. The applications form a market of over $40bn with high single digit CAGR, with the miniature battery component alone worth over $250m."
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
--ENDS--
Enquiries:
| Ilika PlcGraeme Purdy, Chief Executive Jason Stewart, Chief Financial Officer | www.ilika.com Via FTI Consulting |
| Cavendish Capital Markets Limited (Nomad and Broker)Peter Lynch Neil McDonald | +44 (0)131 220 9772 +44 (0)131 220 9771 |
| FTI Consulting (Comms Advisors) Ben Brewerton Elizabeth Adams Dwight Burden | ilika@fticonsulting.com |